Intelligent bio solutions' fda clearance process remains on track for 2025 u.s. launch

New york, march 25, 2025 (globe newswire) -- intelligent bio solutions inc. (nasdaq: inbs) (“inbs” or the “company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today provided shareholders with a status update on the fda clearance process for its intelligent fingerprint drug screening system, which remains on track for launch in the u.s. in 2025 targeting its opiate test system for codeine, as validated in the company's pharmacokinetic (pk) study. on december 18, 2024, the company announced the submission of its 510(k) premarket notification to the u.s. food and drug administration (fda) for review and clearance of its intelligent fingerprinting drug screening system, which the fda classified as a 21 cfr 862.3650, opiate test system, a class ii device requiring submission of a 510(k) premarket notification.
INBS Ratings Summary
INBS Quant Ranking